An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide ( bremelanotide (PT-141)), a melanocortin receptor agonist. Date]Diamond LE, Earle DC, Heiman JR, Rosen RC, Perelman MA, Harning R. Palatin Technologies, Inc., Cranbury, NJ 08512, USA.

INTRODUCTION]AIM: To evaluate a single intranasal dose of bremelanotide for potential effects on physiological and subjective measurements of sexual arousal and desire in premenopausal women with sexual arousal disorder.
MAIN OUTCOME MEASURES][b]RESULTS] More women reported moderate or high sexual desire following bremelanotide treatment vs. placebo (P = 0.0114), and a trend toward more positive responses regarding feelings of genital arousal occurred after bremelanotide compared with placebo (P = 0.0833). Among women who attempted sexual intercourse within 24 hours after treatment, significantly more were satisfied with their level of sexual arousal following bremelanotide, compared with placebo (P = 0.0256). Vaginal vasocongestion did not change significantly while viewing erotic videos following bremelanotide administration compared with placebo.
CONCLUSION]PMID: 16839319 [ PubMed ]